Retatrutide Side Effects: What the Early Trials Show

Retatrutide’s side effects are mostly the familiar gastrointestinal ones seen across weight-loss drugs, but it has one distinctive addition: a skin-tingling sensation called dysesthesia that shows up more at higher doses. The GI effects (nausea, diarrhea, constipation, vomiting) are common but usually mild to moderate, and most people tolerate the drug well enough to continue. Retatrutide is investigational and not FDA approved. Here’s what the trials show about its safety profile.

Why Retatrutide Is Worth Watching on Safety

Retatrutide is a triple agonist, activating three hormone receptors (GIP, GLP-1, and glucagon) rather than one or two. It produces some of the largest weight loss of any drug in development, so its side-effect profile matters a great deal: a very potent drug needs a manageable safety profile to be practical for long-term use. So far, the trials suggest its side effects are largely consistent with the class, with the notable exception of dysesthesia.

The Gastrointestinal Side Effects

As with other GLP-1-based drugs, the most common side effects are digestive, driven by the drug slowing stomach emptying and reducing appetite. The foundational data came from a phase 2 trial published in the New England Journal of Medicine in 2023, which flagged both the gastrointestinal effects and a dose-dependent tingling sensation. Later phase 3 topline results (from the TRIUMPH-1 trial, announced in 2026) reported the following at the highest dose.

These were generally mild to moderate and, as with other drugs in the class, tend to be worst during dose escalation. Discontinuation due to side effects rose with dose, reaching about 11% at the highest dose (versus roughly 5% on placebo), which is manageable but higher than lower doses.

The Dysesthesia Signal

Here’s what sets retatrutide apart. A meaningful share of patients experienced dysesthesia, an abnormal skin sensation often described as tingling or a “pins and needles” feeling. In the phase 3 data, it occurred in roughly 5% to 13% of patients depending on the dose (rising with higher doses), compared with under 1% on placebo. The reassuring part is that these events were generally mild to moderate, the majority resolved during treatment, and most affected participants kept taking the drug. Consider a hypothetical patient on a higher dose who notices some skin tingling in the early months: based on the trial data, it would most likely be mild and fade, though it’s something to report to a provider. The exact mechanism behind this effect isn’t fully understood, and it appears more tied to retatrutide than to GLP-1 drugs generally.

Other Observations

The trials also noted a modest increase in urinary tract infections at higher doses, again generally mild. Because retatrutide includes glucagon activity (which can raise heart rate and affect other parameters), its full long-term safety is still being characterized in the ongoing phase 3 program. As a triple agonist, it’s a newer type of drug, so continued monitoring is appropriate.

Frequently Asked Questions

What is dysesthesia, and should I worry about it?

Dysesthesia is an abnormal skin sensation, often tingling or “pins and needles.” It appeared in a notable share of retatrutide patients at higher doses. In the trials it was generally mild to moderate, usually resolved during treatment, and rarely caused people to stop. It’s worth reporting to a provider but wasn’t a serious problem for most.

Are retatrutide’s side effects worse than other weight-loss drugs?

Its gastrointestinal side effects are broadly similar to the class. The main difference is the dysesthesia (skin tingling) seen more at higher doses, which most other GLP-1 drugs don’t produce to the same degree. Overall tolerability appeared manageable in the trials.

Is retatrutide available yet?

No. Retatrutide is investigational and not FDA approved. It has strong phase 3 topline data, with a regulatory submission anticipated, but it’s currently only available through clinical trials. TrimRx does not offer it.

To focus on treatments available today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.